Nath Bio-Genes (India) Limited has released its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, approved by the Board of Directors at its meeting held on May 04, 2026. The results were reviewed by the Audit Committee on May 02, 2026. The Board has also recommended a final dividend of Rs. 2/- per equity share (i.e., 20%) of face value Rs. 10/- each for FY26, subject to shareholder approval at the ensuing Annual General Meeting.

Standalone Financial Results

On a standalone basis, Nath Bio-Genes reported total revenue from operations of Rs. 43,159.72 Lakhs for FY26, compared to Rs. 36,230.81 Lakhs in FY25. Net profit for the year stood at Rs. 4,442.57 Lakhs versus Rs. 4,214.01 Lakhs in the prior year. For Q4 FY26, revenue from operations was Rs. 4,569.36 Lakhs against Rs. 4,936.76 Lakhs in Q4 FY25. The following table presents the key standalone income statement metrics:

Note: Q4 FY26 figures are balancing figures between audited full-year and year-to-date figures up to Q3. A short provision of Rs. 900.00 Lakhs pertaining to the quarter ended June 2025 has been adjusted in the current quarter.

Standalone Balance Sheet

The standalone balance sheet as at March 31, 2026 reflects total assets of Rs. 1,08,290.24 Lakhs, up from Rs. 1,01,734.63 Lakhs as at March 31, 2025. Equity share capital remained unchanged at Rs. 1,900.40 Lakhs, while other equity (reserves & surplus) grew to Rs. 67,036.62 Lakhs from Rs. 62,966.31 Lakhs. Key balance sheet items are summarised below:

Inventories rose significantly to Rs. 44,459.67 Lakhs from Rs. 33,070.82 Lakhs, while long-term borrowings declined sharply to Rs. 55.34 Lakhs from Rs. 160.87 Lakhs, reflecting continued deleveraging. Cash and cash equivalents stood at Rs. 7,066.79 Lakhs at year-end, comprising cash on hand of Rs. 6.07 Lakhs, current account balances of Rs. 7.19 Lakhs, and term deposits of Rs. 7,053.54 Lakhs.

Consolidated Financial Results

On a consolidated basis, which includes the company's 90% equity stake in Nath Bio-Genes CA, Uzbekistan, total revenue from operations for FY26 was Rs. 44,510.15 Lakhs compared to Rs. 36,490.82 Lakhs in FY25. Net profit for the year stood at Rs. 4,163.03 Lakhs versus Rs. 3,859.98 Lakhs in FY25. For Q4 FY26, consolidated revenue from operations was Rs. 5,159.28 Lakhs. Key consolidated metrics are presented below:

The consolidated balance sheet as at March 31, 2026 reflects total assets of Rs. 1,09,742.28 Lakhs, up from Rs. 1,02,620.75 Lakhs in the prior year. Consolidated other equity stood at Rs. 66,145.48 Lakhs compared to Rs. 62,538.30 Lakhs, while consolidated inventories rose to Rs. 45,054.76 Lakhs from Rs. 33,801.59 Lakhs.

Business and Operational Strengths

The company operates in a single major product segment — Seed Cultivation — with key crops including Jowar, Bajra, Maize, Mustard, and Wheat. Its operational infrastructure includes cold storage facilities, warehouses, and conditioning godowns with a combined capacity of 25,000 MT. The company's R&D capabilities are supported by DSIR-recognised Innovation Centres, a large germplasm repository, and an experienced team of scientists focused on disease and pest resistance breeding. No investor complaints were received or remained pending during the quarter.

Corporate Governance Updates

The Board approved several governance-related decisions at its May 04, 2026 meeting. The Board has recommended the re-appointment of Mr. Hitesh Rajnikant Purohit (DIN: 02340858) as Independent Director, effective March 30, 2027, subject to shareholder approval. Mr. Purohit is a Commerce Graduate with over 30 years of experience in finance and management. Additionally, M/s K.P. Sahasrabudhe & Co., Chartered Accountants — a firm established in 1998 with expertise across tax, corporate, internal, and concurrent audits — has been appointed as Internal Auditors of the company for FY26-27, effective May 04, 2026.

Leadership

The company's leadership team comprises Mr. Nandkishor Kagliwal (Chairman), Mr. Satish Kagliwal (Managing Director), Dr. Capt. Devinder Khurana (Executive Vice President), Mr. Amol Gupta (CFO), Dr. V. N. Kulkarni (Head – R&D), Mr. K. Reddy (Head – Supply Chain), and Mr. Harish Pandey (Business Lead). The audited financial statements were signed off by Managing Director Satish Kagliwal and audited by Gautam N Associates, Chartered Accountants (FRN: 103117W).

Nath Bio-Genes (India) Limited has announced a comprehensive schedule for its Q4FY26 financial results disclosure, including a board meeting on May 4, 2026, followed by an earnings conference call on May 5, 2026. The company issued the board meeting intimation on April 25, 2026, and earnings call notification on April 29, 2026, in compliance with SEBI regulations.

Board Meeting Agenda

The board meeting scheduled for May 4, 2026, will address several critical matters for the company's financial year 2025-26:

Earnings Conference Call Details

Following the board meeting, Nath Bio-Genes will conduct an earnings conference call hosted by Go India Advisors. The call is scheduled for May 5, 2026, at 4:00 PM IST to discuss the Q4FY26 and full-year results.

Management Participation

Key management personnel will participate in the earnings conference call:

Trading Window and Compliance

In accordance with the company's Code of Conduct for prevention of Insider Trading, Nath Bio-Genes has implemented a trading window closure from March 31, 2026, until May 6, 2026. The announcements were made pursuant to Regulations 29, 30, and 33 of the SEBI Listing Regulations 2015, with notifications communicated to both BSE and NSE where the company is listed.

The structured approach to results disclosure demonstrates Nath Bio-Genes' commitment to transparency and regulatory compliance as it concludes financial year 2025-26.